-
Texas A&M Teams With IBM To Speed Drug Discovery For Tuberculosis
6/3/2010
-
Evotec Enters Into Integrated Drug Discovery Alliance With Genentech
6/3/2010
Hamburg, Germany, 2010 (GlobeNewswire via COMTEX) - Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has entered into a multi-year integrated drug discovery alliance with Genentech Inc., a wholly owned member of the Roche Group (SWX:RO) (SIX:ROG) (Pink Sheets:RHHBY), to discover novel small molecule therapeutics
-
immatics Enters Collaboration With The National Cancer Institute (NCI) To Advance The Development Of IMA950 For Glioblastoma
6/2/2010
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, recently announced that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA
-
Teva Announces Launch Of Generic Differin
6/2/2010
Teva Pharmaceutical Industries Ltd. recently announced U.S. Food and Drug Administration (FDA) approval and commercial launch of its generic version of Galderma's product, Differin (adapalene 0.1%) Gel, which is indicated for the treatment of acne. The brand product had annual sales of approximately $91 million in the United States, based on IMS sales data
-
ACADIA Pharmaceuticals To Present At The Ninth Annual Needham Healthcare Conference On June 9, 2010
6/2/2010
ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, recently announced that it will present at the Ninth Annual Needham Healthcare Conference on Wednesday, June 9, 2010 at 3:20 p.m
-
Novella Clinical Inc. Acquires Prologue Research International
6/2/2010
Novella Clinical announced recently the acquisition of Prologue Research International, Inc. (Prologue) an Ohio-based full service Clinical Research Organization (CRO) that focuses exclusively on oncology drug development
-
Celerion Launches New Hybrid ECG Core Lab For Phase I Clinics
6/2/2010
Celerion, the premier provider of innovative early stage clinical research solutions, announces the launch of a new Hybrid Phase I/ ECG Core lab. The Hybrid Phase I/ ECG Core lab provides highly automated ECG analysis for Celerion's global Phase I clinical network. Celerion's highly automated approach employs cutting-edge technology to perform automated measurement of ECG recordings, thereby minimizing cardiologist review and providing clients with faster access to data
-
Ablexis Secures $12 M In Series A Funding To Engineer And Commercialize Next-Generation Platforms For Antibody Drug Discovery
6/2/2010
Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, announced today that it has completed a $12 million Series A financing. The round was led by Third Rock Ventures and included Pfizer Venture Investments
-
Affomix And The University Of Montreal Pharmacogenomics Centre Collaborate On Digital Proteomic Signatures In Pharmacogenomics For Use In Clinical Trials
6/1/2010
Affomix, the pioneer in digital proteomic reagents for next generation molecular assays and the leader in automated, high-throughput monoclonal antibody selection technology, recently announced a collaboration with the internationally recognized University of Montreal Pharmacogenomics Centre (PGx Centre) and the Montreal Heart Institute
-
Yissum Introduces A Breakthrough Computational Method For Superfast Drug Discovery
5/25/2010
Drug discovery and development is a highly risky process, with only one in 10,000 initial candidate compounds reaching the market. When taking into account the aborted candidates, the cost of developing one successful drug may even reach $1 billion, and the development process may take as long as 15-20 years
